Contextlogic Inc. Stock Price, News & Analysis

LogicBio Therapeutics, a clinical-stage genetic medicine company, updated stakeholders on its SUNRISE Phase 1/2 clinical trial, demonstrating in vivo genome editing in pediatric patients with methylmalonic acidemia. Although a serious adverse event occurred during the trial, the company reported the patient has recovered. LogicBio also nominated a new development candidate, LB-401, for hereditary tyrosinemia type 1, showing promising preclinical results. Additionally, Susan R. Kahn was appointed to the Board of Directors, bringing a wealth of experience in rare disease advocacy.

LogicBio Therapeutics (Nasdaq: LOGC) reported their third quarter financial results for 2021, showing a revenue increase to $2.1 million, up from $0.9 million in Q3 2020. R&D expenses rose to $7.8 million, while G&A expenses increased to $4.3 million, leading to a net loss of $10.2 million or $0.31 per share. The company anticipates announcing interim data from its Phase 1/2 SUNRISE trial for LB-001 in pediatric patients with methylmalonic acidemia by year-end. LogicBio holds $59.6 million in cash, funding operations into Q4 2022.

LogicBio Therapeutics (Nasdaq:LOGC) announced its president and CEO, Frederic Chereau, will participate in two upcoming investor conferences. The Barclays Gene Editing & Gene Therapy Summit features a fireside chat on November 15, 2021, at 8:00 a.m. ET. The Jefferies Virtual London Healthcare Conference will have a pre-recorded presentation available starting at 3:00 a.m. ET on November 18, 2021. Both events will be accessible via the Company’s website for 30 days. LogicBio focuses on genetic medicine targeting rare diseases with innovative gene editing and delivery technologies.

LogicBio Therapeutics (Nasdaq: LOGC) presented preclinical data on its GeneRide™ platform at the ESGCT Virtual Congress 2021, showcasing its potential in treating methylmalonic acidemia, hereditary tyrosinemia type 1, and Wilson disease. Findings indicated successful repopulation of diseased livers with corrected hepatocytes, demonstrating reduced toxic metabolite levels and improved liver function. The research highlights GeneRide's selective advantage in liver editing, with important implications for genetic medicine. Additional advancements in the company's AAV technology were also discussed.

LogicBio Therapeutics announced promising results from its Phase 1/2 SUNRISE clinical trial, showcasing the first-ever in vivo genome editing in children with methylmalonic acidemia (MMA). The early data indicated measurable levels of the albumin-2A biomarker, confirming gene insertion and protein expression. Based on the independent Data Safety Monitoring Board's recommendation, the trial will proceed to higher dosing cohorts. LB-001, the investigational therapy utilizing GeneRide™ technology, aims to offer a safe, effective treatment for MMA, a rare genetic disorder with no current therapies.

LogicBio Therapeutics (Nasdaq: LOGC) announced its selection to present new data from the GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, occurring from October 19-22, 2021. The company will deliver a plenary oral presentation on preclinical data showing effective gene delivery in liver conditions, emphasizing the advantages in corrected hepatocyte repopulation. Additionally, three poster presentations will focus on advancements in treating Tyrosinemia Type 1 and optimizing AAV manufacturing processes.

LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Fred Chereau will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:00 a.m. ET. The event will be accessible via a live webcast on the company's investors section of their website, with a replay available for 30 days. LogicBio Therapeutics focuses on gene editing and delivery to address rare diseases using innovative platforms like GeneRide™ and sAAVy™.

LogicBio Therapeutics, a clinical-stage genetic medicine company based in Lexington, MA, announced that its CEO, Fred Chereau, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. The company focuses on gene editing and delivery platforms, including GeneRide for precise gene insertion and sAAVy for optimizing gene delivery.

LogicBio Therapeutics (Nasdaq: LOGC) reported Q2 2021 financial results with revenues of $0.8 million, down from $1.0 million YoY. R&D expenses increased to $7.3 million from $5.9 million, contributing to a net loss of $10.5 million or $0.33 per share. The company highlighted the dosing of the first patient in the SUNRISE trial for LB-001, aimed at treating methylmalonic acidemia (MMA). Strategic partnerships with Daiichi Sankyo and CANbridge Pharmaceuticals were formed, enhancing its GeneRide and sAAVy platforms.